• Seven studies from the NICE SLR were retained for inclusion in this NMA. The SLR update identified a total of 2,456 citations; after deduplication and abstract screening, 239 articles remained; of which 46 full texts were reviewed. Overall, 14 studies from 12 articles with a total of 6,221 patients met the eligibility criteria for inclusion in the NMA.
• Heterogeneity was detected across studies. The proportion of patients with bipolar I disorder in the quetiapine studies varied between 50% and 80.4%, baseline MADRS score varied between 26.9 and 32.0, and in studies reporting weight at baseline values ranged between 63.9kg and 88.8kg.
• The age distribution was similar across included studies, varying between 35.5 and 42.2 years, with the exception of Wang et al., 2014 which recruited younger participants (mean age of 29.2 years). Sensitivity analysis explored the impact of removing the study by Wang et al., 2014.
• The evidence network generated from the studies described in Table 1 is presented in Figure 1 below.
Base case analysis
• NMA results suggested that lurasidone was associated with better efficacy compared to aripiprazole ( • Lurasidone was also associated with better efficacy compared to ziprasidone (mean ΔMADRS: -3.38, 95% Crl: -6.68, -0.11, mean ΔCGI-BP-S: -0. 
BACKGROUND METHODS
• Lurasidone and quetiapine are the only atypical antipsychotics (AAP) currently approved by the US Food and Drug Administration and Health Canada for the management of depressive episodes associated with bipolar disorder as monotherapies.
• Although several placebo-controlled clinical trials have been conducted to assess the efficacy of AAPs for the treatment of patients with bipolar depression, head-to-head data comparing these treatments are lacking.
Identification of trials
• An update of a 2014 systematic literature review (SLR) performed by the National Institute for Health and Care Excellence (NICE) of antipsychotics used for the management of bipolar depression was conducted to identify any new relevant randomized controlled trials (RCTs) by extending the publishing period to May 2015 (1).
• The search strategy was informed by the PICOS (Population, Intervention, Comparison, Outcome and Study type) framework criteria.
• Interventions and comparators included AAPs as monotherapies (lurasidone, quetiapine, olanzapine, aripiprazole, asenapine, risperidone and ziprasidone), and eligible study populations were adults (≥18 years old) with bipolar depression and at least 50% of the population diagnosed with bipolar I disorder.
• Searches were run in EMBASE, MEDLINE, PsycINFO, Cochrane Library and Google Scholar.
Network meta-analysis
• A network meta-analysis was conducted using a Bayesian framework and run using WinBUGS version 1.4.3 (2).
• The methodology employed was based on the NICE Decision Support Unit Technical Support Guidance (3) and published guidance from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Indirect Treatment Comparisons (4,5).
• Both fixed and random effects models were fitted and model fit was assessed using the Deviance Information Criterion and the posterior mean of the total residual deviance. Results from the random effects models are presented as they account for between-study heterogeneity (4).
• Convergence was assessed by visual inspection of density, history and autocorrelation plots.
Outcomes
• Efficacy outcomes included:
-Montgomery-Åsberg Depression Rating Scale total score change from baseline (ΔMADRS) -Clinical Global Impressions -Bipolar Disorder -Severity score for depression change from baseline (ΔCGI-BP-S) -Response (≥50% reduction in MADRS) -Remission (≤12 MADRS at endpoint)
• Tolerability outcomes included:
-Somnolence -Weight change from baseline (Δweight) -Extrapyramidal symptoms (EPS) -All-cause discontinuation
Analyses
• In the base case analysis, quetiapine immediate release and extended release formulations were pooled in one treatment node, aligning with previous network meta-analyses in this therapy area (1,6).
• Sensitivity analysis explored the impact of separating the evidence for the quetiapine immediate release and extended release formulations. 
RESULTS

CONCLUSIONS
Base case analysis (cont.)
• Compared to quetiapine (pooled), lurasidone had similar efficacy but was associated with significantly less weight gain (mean Δweight: -0.83kg, 95% CrI: -1.59, -0.08) and a lower probability of somnolence (mOR: 0.33, 95% CrI: 0.11, 0.82).
• Compared to olanzapine, lurasidone was associated with statistically significantly less weight gain (mean Δweight: -2.54kg, 95% CrI: -3.42, -1.67) and a non-significant lower incidence in somnolence (mOR: 0.56, 95% CrI: 0.18, 1.14).
• The analysis suggested no statistically significant differences in the incidence of EPS for lurasidone versus aripiprazole and quetiapine (pooled).
• Comparisons of lurasidone versus all other comparators for all-cause discontinuation rate did not demonstrate any statistically significant differences as 95% CrI for the ORs generated crossed the OR=1 (data not presented).
Sensitivity analysis
• Sensitivity analysis explored the effect of distinguishing between quetiapine immediate release (QIR) and extended release (QXR) formulations. Results were broadly similar to those derived from the base case.
• Lurasidone was associated with a statistically significantly lower incidence of somnolence compared to QIR (mOR: 0.35, 95% CrI: 0.12, 0.86) and versus QXR (mOR: 0.24, 95% CrI: 0.05, 0.69).
• In the comparison of lurasidone vs. olanzapine, exclusion of Wang et al., 2014 due to potential effect modifiers (age and weight) resulted in a statistically significantly higher response (mOR: 1.73, 95% CrI: 1.05, 2.90) and a greater reduction in mean depressive symptoms (ΔMADRS: -1.28, 95% Crl: -4.17, 1.59) for lurasidone.
Summary of Results
• Results of this study suggested that lurasidone monotherapy was more efficacious than aripiprazole and ziprasidone and had comparable efficacy to olanzapine and quetiapine in the treatment of bipolar depression.
• Lurasidone was associated with a statistically significant reduction in the incidence of somnolence compared to quetiapine and ziprasidone.
• Lurasidone was associated with less weight gain than both olanzapine and quetiapine.
Study limitations
• A small number of RCTs were available for inclusion in the network. In addition, original studies were not powered to detect statistically significant differences in the context of network meta-analysis.
• Heterogeneity was detected across included studies in terms of baseline patient characteristics, which may act as effect modifiers in the efficacy and the incidence of side effects.
• Meta-regression (which can potentially adjust for effect modifiers) was not run due to the absence of a sufficiently large number of trials informing each comparison that is required to render meta-regression feasible at the aggregate level.
• Studies assessed the efficacy and safety data at either six or eight weeks; the extent to which time point measurement might act as a treatment effect modifier has not been explored in the analysis.
• The studies included in the evidence network used different imputation methods for the handling of missing data; therefore, comparability of continuous efficacy measures may be limited in some cases. 
Figure 1. Network of evidence
• In the absence of head-to-head clinical trials, results from this network meta-analysis suggest that lurasidone, an approved second-generation antipsychotic for bipolar depression, was as efficacious as quetiapine and olanzapine monotherapies, and was more efficacious than aripiprazole and ziprasidone for the treatment of bipolar depression. Aripiprazole and ziprasidone failed to demonstrate efficacy in clinical controlled trials.
• Lurasidone was associated with statistically significant less weight gain and a lower likelihood of somnolence as compared to quetiapine and olanzapine.
• No statistically significant differences were observed in the incidence of EPS for lurasidone versus aripiprazole and quetiapine.
• Head-to-head effectiveness studies comparing the relative clinical efficacy, safety and tolerability of atypical antipsychotic monotherapies in patients with bipolar depression are warranted to confirm these findings.
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DISCLOSURES
• In the absence of comparative trials, a network meta-analysis (NMA) was conducted to assess the relative efficacy and tolerability of lurasidone monotherapy compared to other AAPs for the management of bipolar depression.
OBJECTIVE
